Cover Image
市場調查報告書

家族性類澱粉沈積神經病變:開發中產品分析

Familial Amyloid Neuropathies - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 362374
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
家族性類澱粉沈積神經病變:開發中產品分析 Familial Amyloid Neuropathies - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 76 Pages
簡介

本報告提供家族性類澱粉沈積神經病變治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

家族性類澱粉沈積神經病變概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

家族性類澱粉沈積神經病變:企業開發中的治療藥

家族性類澱粉沈積神經病變:大學/機關研究中的治療藥

家族性類澱粉沈積神經病變:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

家族性類澱粉沈積神經病變:企業開發中的產品

家族性類澱粉沈積神經病變:大學/機關研究中的產品

家族性類澱粉沈積神經病變的治療藥的開發企業

  • Alnylam Pharmaceuticals, Inc.
  • Bsim2
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • SOM Innovation Biotech SL

家族性類澱粉沈積神經病變:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

家族性類澱粉沈積神經病變:最近的開發平台趨勢

家族性類澱粉沈積神經病變:暫停中的計劃

家族性類澱粉沈積神經病變:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8205IDB

Summary

Global Markets Direct's, 'Familial Amyloid Neuropathies - Pipeline Review, H1 2016', provides an overview of the Familial Amyloid Neuropathies pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Familial Amyloid Neuropathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Amyloid Neuropathies and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Familial Amyloid Neuropathies
  • The report reviews pipeline therapeutics for Familial Amyloid Neuropathies by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Familial Amyloid Neuropathies therapeutics and enlists all their major and minor projects
  • The report assesses Familial Amyloid Neuropathies therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Familial Amyloid Neuropathies

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Familial Amyloid Neuropathies
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Familial Amyloid Neuropathies pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Familial Amyloid Neuropathies Overview
  • Therapeutics Development
    • Pipeline Products for Familial Amyloid Neuropathies - Overview
    • Pipeline Products for Familial Amyloid Neuropathies - Comparative Analysis
  • Familial Amyloid Neuropathies - Therapeutics under Development by Companies
  • Familial Amyloid Neuropathies - Therapeutics under Investigation by Universities/Institutes
  • Familial Amyloid Neuropathies - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Familial Amyloid Neuropathies - Products under Development by Companies
  • Familial Amyloid Neuropathies - Products under Investigation by Universities/Institutes
  • Familial Amyloid Neuropathies - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Bsim2
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • SOM Innovation Biotech SL
  • Familial Amyloid Neuropathies - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CLR-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • doxycycline hyclate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • inotersen sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • patisiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tafamidis meglumine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tolcapone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Familial Amyloid Neuropathies - Recent Pipeline Updates
  • Familial Amyloid Neuropathies - Dormant Projects
  • Familial Amyloid Neuropathies - Product Development Milestones
    • Featured News & Press Releases
      • May 26, 2016: Ionis Pharmaceuticals Provides Update on IONIS-TTR Rx Program
      • Apr 20, 2016: Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
      • Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
      • Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
      • Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting
      • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
      • Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
      • Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update
      • Sep 28, 2015: Alnylam and Collaborators Report First-Ever Evidence that Patisiran Reduces Pathogenic, Misfolded Transthyretin Monomers and Oligomers in TTR-Mediated Amyloidosis Patients with Familial Amyloidotic Polyneuropathy
      • Jul 20, 2015: Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Familial Amyloid Neuropathies, H1 2016
  • Number of Products under Development for Familial Amyloid Neuropathies - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Familial Amyloid Neuropathies - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Familial Amyloid Neuropathies - Pipeline by Bsim2, H1 2016
  • Familial Amyloid Neuropathies - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Familial Amyloid Neuropathies - Pipeline by Pfizer Inc., H1 2016
  • Familial Amyloid Neuropathies - Pipeline by SOM Innovation Biotech SL, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Familial Amyloid Neuropathies Therapeutics - Recent Pipeline Updates, H1 2016
  • Familial Amyloid Neuropathies - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Familial Amyloid Neuropathies, H1 2016
  • Number of Products under Development for Familial Amyloid Neuropathies - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top